Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRS + Akkermansia muciniphila
- Development stage
- Preclinical
- Lead developer
- Akkermansia
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A synbiotic combination consisting of the prebiotic Puerariae lobatae Radix-resistant starch (PRS) and the probiotic *Akkermansia muciniphila* (AKK). This combination is being investigated for the treatment of ischemic stroke by modulating the gut-brain axis. PRS selectively enriches AKK, which produces the metabolite indole lactic acid (ILA). ILA acts as a ligand for the aryl hydrocarbon receptor (AhR) and activates the Nrf2 signaling pathway. This activation leads to the upregulation of ferroptosis-inhibiting proteins, specifically SLC7A11 and GPX4, thereby reducing neuronal damage and intestinal injury following an ischemic stroke. Preclinical studies in rat models have shown that this synbiotic approach is more effective than either component alone in alleviating stroke-induced damage.
- Other names
- Puerariae lobatae Radix-resistant starch + Akkermansia muciniphilaPRS + AKKPuerariae lobatae Radix-resistant starch + Akkermansia muciniphila synbiotic
02
Targets
ICAM2 (ICAM-2)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)AHR (Aryl hydrocarbon receptor)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on PRS + Akkermansia muciniphila.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRS + Akkermansia muciniphila.